| Literature DB >> 31772085 |
Nut Koonrungsesomboon1, Chanchai Traivaree2, Charnunnut Tiyapsane2, Juntra Karbwang3.
Abstract
OBJECTIVE: This study was designed to evaluate the applicability and effectiveness of the enhanced informed consent form (ICF) methodology, proposed by the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER), in paediatric research requiring parental consent. The objective of this study was to compare the parental understanding of information between the parents who read the SIDCER ICF and those who read the conventional ICF.Entities:
Keywords: comprehension; consent forms; informed consent; parental consent; pediatrics
Mesh:
Year: 2019 PMID: 31772085 PMCID: PMC6887000 DOI: 10.1136/bmjopen-2019-029530
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow diagram of this ICF study.
Demographic data of the parents (n=210)
| SIDCER ICF | Conventional ICF | |||
| Gender (n) | ||||
| Male | 30 | (28.6%) | 27 | (25.7%) |
| Female | 75 | (71.4%) | 78 | (74.3%) |
| Age (year) | 33.9±12.7 | 37.4±13.3 | ||
| Education (n) | ||||
| High school or below | 49 | (46.7%) | 33 | (31.4%) |
| Bachelor degree or above | 56 | (53.3%) | 72 | (68.6%) |
Data represent the number (percentage) of parents or mean±SD.
Comparisons of the total score, the score in each category of the ICF content and time spent between the two groups
| SIDCER ICF | Conventional ICF | Mean difference | 95% | P value* | Effect size† | |
| Total score (out of 24) | 18.07±3.71 | 15.98±4.56 | 2.09 | (0.96 to 3.22) | <0.001 | 0.49 |
| Score in the general items (out of 5) | 3.99±1.05 | 3.71±1.16 | 0.28 | (-0.03 to 0.58) | 0.072 | 0.25 |
| Score in the patient’s rights (out of 4) | 3.41±0.83 | 3.23±1.07 | 0.18 | (-0.08 to 0.44) | 0.172 | 0.19 |
| Score in the scientific aspects (out of 8) | 5.51±1.70 | 4.50±1.80 | 1.02 | (0.54 to 1.50) | <0.001 | 0.56 |
| Score in the ethics aspects (out of 7) | 5.15±1.52 | 4.54±1.74 | 0.61 | (0.17 to 1.05) | 0.007 | 0.37 |
| Time spent reading a given ICF (minutes) | 23.61±12.51 | 30.90±15.45 | −7.30 | (-11.12 to −3.47) | <0.001 | 0.50 |
| Time spent completing the questionnaire (minutes) | 24.48±12.84 | 30.59±13.29 | −6.11 | (-9.67 to −2.56) | 0.001 | 0.46 |
Data represent mean±SD.
*Student t-test.
†Cohen’s d value.
Comparisons of the parental understanding of each element of the ICF content between the two groups
| SIDCER ICF | Conventional ICF (n=105) | Relative risk (95% CI) |
| ||||
| General items | |||||||
| 1. Recognition that this is research | 80 | (76.2%) | 78 | (74.3%) | 1.026 | (0.878–1.198) | 0.749 |
| 2. Subjects’ responsibility | 85 | (81.0%) | 84 | (80.0%) | 1.012 | (0.886–1.156) | 0.862 |
| 3. Confidentiality of records | 74 | (70.5%) | 64 | (61.0%) | 1.156 | (0.950–1.408) | 0.146 |
| 4. Who can access the data | 82 | (78.1%) | 68 | (64.8%) | 1.206 | (1.014–1.435) | 0.032 |
| 5. Research contact persons | 98 | (93.3%) | 96 | (91.4%) | 1.021 | (0.944–1.103) | 0.603 |
| Patient’s rights | |||||||
| 6. Right to refuse | 76 | (72.4%) | 87 | (82.9%) | 0.874 | (0.754–1.012) | 0.069 |
| 7. Right to withdraw | 95 | (90.5%) | 87 | (82.9%) | 1.092 | (0.981–1.215) | 0.104 |
| 8. Consequences of withdrawal | 96 | (91.4%) | 87 | (82.9%) | 1.103 | (0.994–1.225) | 0.064 |
| 9. Right to receive new information | 91 | (86.7%) | 78 | (74.3%) | 1.167 | (1.019–1.336) | 0.024 |
| Scientific aspects | |||||||
| 10. Eligibility of the subject | 81 | (77.1%) | 72 | (68.6%) | 1.125 | (0.953–1.328) | 0.163 |
| 11. Number of subjects required | 87 | (82.9%) | 43 | (41.0%) | 2.023 | (1.583–2.587) | <0.001 |
| 12. Purpose of the study | 80 | (76.2%) | 75 | (71.4%) | 1.067 | (0.908–1.254) | 0.433 |
| 13. Trial treatment and random assignment | 38 | (36.2%) | 28 | (26.7%) | 1.357 | (0.904–2.038) | 0.137 |
| 14. Trial procedures | 65 | (61.9%) | 52 | (49.5%) | 1.250 | (0.979–1.596) | 0.071 |
| 15. Identification of experimental procedures | 80 | (76.2%) | 66 | (62.9%) | 1.212 | (1.011–1.454) | 0.036 |
| 16. Duration of the subject’s participation | 88 | (83.8%) | 79 | (75.2%) | 1.114 | (0.970–1.279) | 0.124 |
| 17. Storage and reuse of human materials | 60 | (57.1%) | 57 | (54.3%) | 1.053 | (0.827–1.340) | 0.677 |
| Ethics aspects | |||||||
| 18. Alternative course of treatment | 94 | (89.5%) | 82 | (78.1%) | 1.146 | (1.016–1.293) | 0.025 |
| 19. Foreseeable risks | 70 | (66.7%) | 61 | (58.1%) | 1.148 | (0.929–1.418) | 0.200 |
| 20. Expected direct/indirect benefits | 52 | (49.5%) | 42 | (40.0%) | 1.238 | (0.914–1.677) | 0.165 |
| 21. Post-trial benefits | 82 | (78.1%) | 72 | (68.6%) | 1.139 | (0.966–1.342) | 0.119 |
| 22. Prorated payment for participation | 91 | (86.7%) | 84 | (80.0%) | 1.083 | (0.959–1.223) | 0.195 |
| 23. Anticipated expenses | 60 | (57.1%) | 53 | (50.5%) | 1.132 | (0.880–1.456) | 0.333 |
| 24. Compensation for injury | 92 | (87.6%) | 83 | (79.0%) | 1.108 | (0.981–1.252) | 0.096 |
Data represent the number (percentage) of parents. *χ2 test.